JPRN-UMIN000027655已完成未知
A phase II study of osimertinib in patients with poor performance status and EGFR mutation T790M-positive non-small-cell lung cancer - A phase II study of osimertinib in patients with poor performance status and EGFR mutation T790M-positive non-small-cell lung cancer
Division of Thoracic Oncology, Shizuoka cancer center0 个研究点目标入组 18 人开始时间: 2017年6月7日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 18
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1)History of using third-generation EGFR-TKI 2)Uncontrolled symptomatic brain metastasis 3)Interstitial pneumonia or pulmonary fibrosis on imaging 4)QTc > 500 msec 5)Gastrointestinal disorder 6)Uncontrollable pleural effusion , ascites or pericardial effusion 7)Receiving the radiation therapy for chest 8)28th or less days from the last dosage of immunocheckpoint therapy 9)Severe complication
研究者
相似试验
招募中
不适用
Phase II study of osimertinib in patients with non-small cell lung cancer who acquired resistance to afatinibon-small cell lung cancerJPRN-UMIN000028166Asahikawa Medical University Hospital50
已完成
不适用
Observational study of osimertinib for patients with locally advanced/metastatic non-small cell lung cancer who are harboring T790M mutation detected by liquid biopsy and whose disease has progressed with previous EGFR-TKI therapy(WJOG8815LFS)EGFR mutation positive advanced or metastatic NSCLCJPRN-UMIN000034682West Japan Oncology Group33
已完成
2 期
E-LiquidJPRN-jRCT2080225059Department of Thoracic Oncology, National Cancer Center Hospital East91
进行中（未招募）
2 期
A Phase 2 Study of Osimertinib in combination with Platinum-pemetrexed in patients with EGFR-mutated Advanced non-small cell Lung cancer.on-squamous non-small cell lung cancerJPRN-jRCTs031180226Kobayashi Kunihiko66
招募中
4 期
Efficacy study of osimertinib in treatment-naïve patients with EGFR mutant NSCLC according to TP53 mutational status (TEMPLE-2)2024-517424-18-00Fondazione Policlinico Universitario Agostino Gemelli IRCCS54